SEC Tracker
Get the app

Possible new BIAF shares

BIAFDilution

Last raise Nov 2, 2026, 424B5: 115K shares (1.4% of the 8.1M then)

Known so far: no new shares from the prospectus covers read · shelf room about $7.5M · not yet read: warrants, converts, options.

Shelf room

  • Room today about $7.5M
  • One third of float $7.5M ($22.6M float, Jun 30, 2025)
  • Sold off it, 12 months nothing
How this is worked out

Shelf room about $7.5M on the S-3 of Sep 3, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $22.6M public float stated as of Jun 30, 2025, $7.5M, nothing sold off it in the last 12 months. Sources: S-3/A Sep 3, 2026, effective Sep 4, 2026 · public float, as of Jun 30, 2025.

What could become new bioAffinity Technologies (BIAF) shares: an ATM program, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.

BIAF dilution ladder

Every source of new shares on record, from the filings that created it.

8.1M outstanding; up to 9.9M fully diluted, +22%

  1. Outstandingas of Aug 3, 2026 (10-Q filed Aug 7) · share count on the cover page
    8.1M
  2. At-the-market program$5.2M program424B5 Nov 2, 2026 · At-the-market prospectus supplementat $2.91, stated in the filing on Oct 30
    +1.8M

Not stated in the filings we read: warrants, convertible notes, options and RSUs.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Financing terms to know

None found in filings since Nov 2, 2026.

Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.

Shares outstanding

8.1M

Nov 2024 to Aug 2026: from 503K to 8.1M. Adjusted for the 1-for-31 reverse split by Nov 11, 2025: each earlier count is divided by the ratio of every split after it.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.